Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

121. Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation Full Text available with Trip Pro

Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation Fatty liver disease is increased among individuals with HIV. We sought to explore how aldosterone, a key hormone linked to insulin resistance and inflammation, relates to liver fat in the large population of individuals with HIV and metabolic abnormalities.Forty-six individuals with HIV and increased waist circumference and dysglycemia were assessed for liver fat using proton (...) [8% (3%, 20%) vs 4% (2%, 10%); P = 0.02]. In the presence of metabolic syndrome, individuals with aldosterone levels above vs below the median had markedly elevated liver fat values [14% (9%, 23%) vs 5% (3%, 12%); P = 0.005] and increased presence of fatty liver disease (FLD; 92% vs 50%; P = 0.02). Controlling for metabolic syndrome, hepatitis C virus, and alcohol use, aldosterone was a significant and independent predictor of liver fat (β estimate: 0.6038, P = 0.01; overall model r2 = 0.41, P

2018 Journal of the Endocrine Society

122. Health care users’ knowledge, attitudes and perceptions of HIV self-testing at selected gateway clinics at eThekwini district, KwaZulu-Natal province, South Africa Full Text available with Trip Pro

Health care users’ knowledge, attitudes and perceptions of HIV self-testing at selected gateway clinics at eThekwini district, KwaZulu-Natal province, South Africa Progress in promoting knowledge of HIV status has been made globally, but half of all people living with HIV are still unaware of their HIV status. It is argued the new innovative HIV self-testing strategy could increase the uptake of HIV testing among the people. The aim of the study was to assess outpatients' health care user's (...) knowledge, attitudes and perceptions towards HIV self-testing (HIVST) at selected Gateway clinics at eThekwini District, KwaZulu-Natal Province, South Africa. The objectives of the study were to determine health care users' knowledge of HIVST, assess health care users' attitudes and perceptions towards HIVST and establish if there is any relationship between knowledge, attitudes and perceptions of health care users towards HIVST. A quantitative, non-experimental descriptive design was used to determine

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

123. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Full Text available with Trip Pro

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. People who inject drugs (PWID) have a high incidence of HIV, little access to antiretroviral therapy (ART) and medication-assisted treatment (MAT), and high mortality. We aimed to assess the feasibility of a future controlled trial based on the incidence of HIV, enrolment, retention, and uptake (...) of the intervention, and the efficacy of an integrated and flexible intervention on ART use, viral suppression, and MAT use.This randomised, controlled vanguard study was run in Kyiv, Ukraine (one community site), Thai Nguyen, Vietnam (two district health centre sites), and Jakarta, Indonesia (one hospital site). PWID who were HIV infected (index participants) and non-infected injection partners were recruited as PWID network units and were eligible for screening if they were aged 18-45 years (updated to 18-60

2018 Lancet Controlled trial quality: predicted high

124. Considerations for the clinical management of HIV elite controllers

or undetectable viral loads, so there is a risk that their HIV infection may be misdiagnosed (9, 10). However, there are no testing algorithms specific to elite controllers (11, 12). While elite controllers are able to control their HIV infection, they continue to experience ongoing inflammation, decreases in CD4+ T cells, inflammation-associated cardiovascular disease and high rates of cancer, which suggest that their natural ability to control the virus over the long term may be coming at an immunologic (...) ). This review is focused specifically on elite controllers. It is important to understand the mechanisms underlying elite control of HIV — particularly in those individuals who have undetectable virus AND normal CD4 counts for at least 10 years — because it may represent a natural model for a “functional cure” (i.e. long term control of viral replication and remission from symptoms of HIV infection in the absence of antiretroviral therapy) (13, 17). The exact mechanisms of elite control remain unclear (18

2018 Ontario HIV Treatment Network

125. Dolutegravir rilpivirine (Juluca) - For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA copies <50 copies/mL) on a stable antiretroviral regimen

Dolutegravir rilpivirine (Juluca) - For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA copies <50 copies/mL) on a stable antiretroviral regimen Published 10 September 2018 1 dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca ® ) SMC2091 ViiV Healthcare Ltd. 10 August 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission dolutegravir / rilpivirine film-coated tablet (Juluca ® ) is accepted for use within NHSScotland. Indication under review: The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA 50 copies/mL in the 6-month period before screening and no more than one instance of viral load >50 copies/mL but <200 copies/mL

2018 Scottish Medicines Consortium

126. Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy) - For the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.

and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy ® ) is accepted for use within NHSScotland. Indication under review: Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir / emtricitabine / tenofovir alafenamide was non (...) of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of bictegravir / emtricitabine / tenofovir alafenamide. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower. Chairman Scottish Medicines Consortium 2 Indication Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. 1

2018 Scottish Medicines Consortium

127. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

-OLE) [7] enrolled 1603 HIV-negative men and 339 (14%) trans women who have sex with men who were previously part of PrEP studies (iPrEx, ATN082/Project PrEPare and CDC MSM Safety Trial). Participants were offered daily TDF-FTC and were followed up for 72 weeks after enrolment. Uptake was high at 76%, and this was higher among those reporting condomless receptive anal intercourse and those who were herpes simplex-2 virus (HSV-2) seropositive, suggesting use during periods of risk. HIV incidence (...) - up there were no new HIV infections in the men enrolled in the programme [9]. At the time of writing there have been three case reports of HIV transmissions in MSM taking PrEP despite apparent confirmed adherence. Two individuals were infected with resistant virus and, in one case, transmission occurred with wild-type virus sensitive to both tenofovir and emtricitabine [10]. 4.1 Evidence for safety and efficacy in men who have sex with men (MSM): recommendations 1. We recommend that PrEP

2018 British HIV Association

128. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

studies The iPrEx Open-label Extension (iPrEx-OLE) [7] enrolled 1603 HIV-negative men and 339 (14%) trans women who have sex with men who were previously part of PrEP studies (iPrEx, ATN082/Project PrEPare and CDC MSM Safety Trial). Participants were offered daily TDF-FTC and were followed up for 72 weeks after enrolment. Uptake was high at 76%, and this was higher among those reporting condomless receptive anal intercourse and those who were herpes simplex-2 virus (HSV-2) seropositive, suggesting use (...) . After a maximum of 16 months’ follow- up there were no new HIV infections in the men enrolled in the programme [9]. At the time of writing there have been three case reports of HIV transmissions in MSM taking PrEP despite apparent confirmed adherence. Two individuals were infected with resistant virus and, in one case, transmission occurred with wild-type virus sensitive to both tenofovir and emtricitabine [10]. 4.1 Evidence for safety and efficacy in men who have sex with men (MSM): recommendations

2018 British Association for Sexual Health and HIV

129. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection Full Text available with Trip Pro

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection The objective of the study was to evaluate the role of a clinical pharmacist in hepatitis C virus (HCV) treatment of patients living with HIV/HCV coinfection.We conducted a descriptive study to quantify the functions of a clinical pharmacist in HCV treatment of patients living with HIV/HCV coinfection who were initiating HCV treatment at a publicly funded (...) clinic between March 18, 2015 and September 15, 2016. The clinical pharmacist's role was categorized into eight categories: 1) HCV prior authorization (PA) completion; 2) HCV medication adherence counseling; 3) HCV drug-drug interaction (DDI) counseling and screening; 4) HCV medication counseling regarding common adverse events (AEs); 5) HCV counseling regarding HCV treatment outcomes and risk of reinfection; 6) ordering laboratory tests and interpretation of HCV laboratory values; 7) HIV medication

2018 Integrated pharmacy research & practice

130. Effect of a multicomponent behavioural PMTCT cluster randomised controlled trial on HIV stigma reduction among perinatal HIV positive women in Mpumalanga province, South Africa Full Text available with Trip Pro

Effect of a multicomponent behavioural PMTCT cluster randomised controlled trial on HIV stigma reduction among perinatal HIV positive women in Mpumalanga province, South Africa We evaluate the impact a multicomponent, behavioural, prevention of mother to child transmission (PMTCT), cluster randomised controlled trial on HIV stigma reduction among perinatal HIV infected women in rural South Africa.In a cluster randomised controlled trial, twelve community health centres (CHCs) in Mpumalanga (...) Province, South Africa, were randomised; pregnant women living with HIV enrolled received either: A Standard Care (SC) condition plus time-equivalent attention-control on disease prevention (SC; 6 CHCs; n =357), or an Enhanced Intervention (EI) condition of SC PMTCT plus the 'Protect Your Family' intervention (EI; 6 CHCs; n =342). HIV-infected pregnant women in the SC attended four antenatal and two postnatal video sessions; those in the EI, four antenatal and two postnatal group PMTCT sessions

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance Controlled trial quality: uncertain

131. HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. Full Text available with Trip Pro

HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. Because HIV viral suppression is essential for optimal outcomes and prevention efforts, understanding trends and predictors is imperative to inform public health policy.To evaluate viral suppression trends in people living with HIV (PLWH), including the relationship of associated factors, such as demographic characteristics and integrase strand transfer inhibitor (...) (ISTI) use.Longitudinal observational cohort study.8 HIV clinics across the United States.PLWH receiving clinical care.To understand trends in viral suppression (≤400 copies/mL), annual viral suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited to 1 random test per person per year and using inverse probability of censoring weights to address loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH receiving antiretroviral

2018 Annals of Internal Medicine

132. Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women Full Text available with Trip Pro

Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women Purpose There is a dearth of data on clearance of cervical human papillomavirus (HPV) infection among women in West Africa. We examined the clearance of low-risk (lr) and high-risk (hr) cervical HPV infections, and the factors associated with these measures in HIV-negative and HIV-positive women. Methods We studied 630 Nigerian women involved in a study of HPV (...) infection using short polymerase chain reaction fragment-10 assay and line probe assay-25. Research nurses used a cervical brush to collect samples of exfoliated cervical cells from all the study participants. Cox proportional hazards models were used to estimate associations between HIV and HPV infections. Results The mean age of the study participants was 38 (standard deviation, ± 8) years; 51% were HIV positive. The rate of clearing any HPV infection was 2.0% per month among all women in the study

2018 Journal of global oncology

133. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study Full Text available with Trip Pro

The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study As countries embark on public health-oriented drug law reform, health impact evaluations are needed. In 2012, Mexico mandated the narcomenudeo reform, which depenalised the possession of small amounts of drugs and instituted drug treatment instead of incarceration. We investigated the past and future effect of this drug law reform on HIV incidence (...) in people who inject drugs in Tijuana, Mexico.In this epidemic modelling study, we used data from the El Cuete IV cohort study to develop a deterministic model of injecting and sexual HIV transmission in people who inject drugs in Tijuana between 2012 and 2030. The population was stratified by sex, incarceration status, syringe confiscation by the police, HIV stage, and exposure to drug treatment or rehabilitation (either opioid agonist treatment or compulsory drug abstinence programmes). We modelled

2018 The Lancet. Public health

134. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. Full Text available with Trip Pro

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4.In this single-group, open-label, phase 3 study, we enrolled 40 adults with multidrug-resistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed. All the patients had a viral load of more than 1000 copies of HIV-1 RNA per milliliter. After a 7-day control period (...) of susceptibility to ibalizumab than at baseline. The most common adverse event was diarrhea (in 20% of patients). Four patients died from causes related to underlying illnesses; 1 had a serious adverse event (the immune reconstitution inflammatory syndrome) that was deemed to be related to ibalizumab therapy.In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-week study. Evidence of the emergence of diminished

2018 NEJM

135. HIV

contact us via jon.brassey@tripdatabase.com Top results for hiv 1. HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS - Summary The Human Immunodeficiency Virus ( HIV ) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV : HIV -1 (the predominant type in the UK) is highly virulent and is found (...) Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV . Key considerations concerning the issue 2011 9. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes

2018 Trip Latest and Greatest

136. Biomedical and Behavioral Outcomes of Keep It Up!: An eHealth HIV Prevention Program RCT Full Text available with Trip Pro

Biomedical and Behavioral Outcomes of Keep It Up!: An eHealth HIV Prevention Program RCT HIV diagnoses among young men who have sex with men are increasing, but few effective HIV prevention interventions exist for this population. An RCT was conducted of the online Keep It Up! intervention to determine if it significantly reduced condomless anal sex and sexually transmitted infections compared with an HIV knowledge condition.From May 2013 to March 2017, a total of 901 participants were enrolled (...) in a double-blinded RCT of Keep It Up! with 1-year follow-up. After completing baseline surveys and sexually transmitted infection testing, participants were randomized by an eHealth platform to the intervention or control condition.HIV-negative men who have sex with men reporting condomless anal sex, aged 18-29 years, were recruited through advertising and from HIV testing sites and outreach in Atlanta, Georgia; Chicago, Illinois; and New York, New York.Multimedia was used to address HIV knowledge

2018 EvidenceUpdates

137. Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 New pharmacokinetic data show (...) mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta▼, Symtuza▼) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. Published 17 July 2018 From: Therapeutic area: , , , Contents Advice for healthcare professionals: pharmacokinetic data show low

2018 MHRA Drug Safety Update

138. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance

is underpinned by two guiding principles: promoting human rights and promoting gender equality. Source: Consolidated guideline on sexual and reproductive health and rights of women living with HIV (3).Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 6 Fig. 1. Example of an algorithm for programmatic implementation of DTG a TLD (fixed-dose combination of TDF + 3TC + DTG) could be considered (...) and the proportion of HIV-uninfected infants that would potentially start treatment unnecessarily. Note that the cycle threshold values vary by the assay used and cannot be directly applied between technologies or assays. Further, additional considerations may be necessary for countries using plasma as a sample type for infant testing rather than whole blood or dried blood spots, since the latter sample types typically capture and amplify intracellular nucleic acids that may increase the detected levels of virus

2018 World Health Organisation HIV Guidelines

139. Correlates of Not Using Antiretroviral Therapy Among Transwomen Living with HIV: The Unique Role of Personal Competence Full Text available with Trip Pro

Correlates of Not Using Antiretroviral Therapy Among Transwomen Living with HIV: The Unique Role of Personal Competence Purpose: This study tested three psychosocial measures for their potential to serve as counseling goals for promoting ART to transgender women living with HIV (TWLH). Methods: Among 69 TWLH, 17.4% were not taking ART; these volunteers were compared to the remainder using multivariate regression analyses. Results: Only one psychosocial measure achieved significance: Personal

2018 Transgender health

140. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class (...) Practice GEN elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated; Genvoya®) GI gastrointestinal GLSM geometric least-squares mean GS-9883 bictegravir HBeAb hepatitis B e antibody HBeAg hepatitis B e antigen HBsAb hepatitis B surface antibody HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HDPE High Density Polyethylene HIV human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HLA human leukocyte antigen HPLC High performance liquid

2018 European Medicines Agency - EPARs